VivoSeq
Metabolic & Endocrine

Hyperuricemia

39

Pipeline Programs↗

6

Active Trials↗

19

Companies Involved↗

Hyperuricemia is a moderately active landscape with 39 programs across 19 companies. The most active players are Novo Nordisk, Shenyang Sunshine Pharmaceutical Co., LTD., Parkedale. 10 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

94/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

1 program

Phase 1S

Shenyang Sunshine Pharmaceutical Co., LTD.

1 program

Phase 1P

Parkedale

1 program

Phase 1N

Nuon Therapeutics, Inc.

3 programs

Phase 2U

Urica Therapeutics Inc.

2 programs

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

46 of 48 classified programs — the dominant modality here.

4%ALL OTHERSProtein / enzyme24%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 100% of 48 pipeline programs.

Analysis

Trial Status

52

clinical trials

Completed31 · 60%
Unknown status13 · 25%
Recruiting3 · 6%
Not yet recruiting2 · 4%
Terminated2 · 4%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

52 trials

Effect of Dotinurad in Hyperuricemia With Hypertension
Recruiting·—·Phase 4·NCT06834230·360 enrolled
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT06629376·60 enrolled
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT06859073·60 enrolled
Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
Active, not recruiting·GGuangzhou Ruianbo Pharmaceutical Technology Co., Ltd·Phase 2/3·NCT06603142·636 enrolled
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07362355·340 enrolled
Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06414837·434 enrolled
Nutraceutical on Hyperuricemia
Completed·UUniversity of Pavia·Phase 4·NCT04161872·116 enrolled
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03185793·198 enrolled
Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
Completed·—·N/A·NCT03149939·19 enrolled
Rasburicase for Hyperuricemia
Completed·Sanofi logoSanofi·Phase 2·NCT00290992·30 enrolled
Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia
Completed·SShanghai 10th People's Hospital·Phase 4·NCT05496075·72 enrolled
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
Completed·NNuon Therapeutics, Inc.·Phase 2·NCT01052987·24 enrolled
Genetics of Hyperuricemia Therapy in Hmong
Completed·UUniversity of Minnesota·N/A·NCT02371421·80 enrolled
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Completed·LLG Chem·Phase 2·NCT03934099·156 enrolled
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
Completed·AAtom Therapeutics Co., Ltd·Phase 2·NCT04638543·60 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)